Achieving Nutritional Adequacy Of Vitamin K With An Egg/Plant-Based Food Pairing

NCT ID: NCT04286321

Last Updated: 2025-06-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2024-07-15

Brief Summary

Malnutrition of the fat-soluble nutrient vitamin K (phylloquinone; PQ) is problematic. Since PQ is rich in plant foods (e.g. spinach) that are mostly absent of accessible lipid, dietary patterns that can potentiate PQ bioavailability by pairing vegetables with lipid-rich foods have been emphasized. The purpose of this study is to use deuterium-labeled spinach (containing stable isotopes of PQ) to validate eggs as a dietary tool to improve PQ bioavailability directly from a model plant food, and hence achieve nutrient adequacy. It is expected that compared with deuterium-labeled spinach alone, co-ingestion of eggs will increase plasma bioavailability of spinach-derived deuterium-labeled PQ without affecting time to maximal concentrations or half-lives. Further, phospholipid-rich egg yolk lipid will enhance nutrient bioavailability compared with vegetable oil. The outcomes will serve as the foundation for easy-to-implement message of public health importance in support of whole eggs and egg whites as part of a plant-based dietary pattern.

Detailed Description

In the US, 43-63% of men and women do not meet recommended intakes for PQ. Dietary recommendations strongly encourage a diet rich in fruits and vegetables to meet dietary PQ requirements. However, PQ bioavailability from most plant foods is quite poor, thereby emphasizing a need for effective food pairings that can enhance the absorption and promote adequate status of these health-promoting nutrients. The objective of this study is to demonstrate that an effective food pairing of spinach with phospholipid lipid-rich eggs promotes intestinal absorption of spinach-derived PQ, and hence achieve nutrient adequacy. Our hypothesis is that the bioavailability of PQ from deuterium-labeled spinach will be potentiated by egg intake in a dose-dependent manner by increasing their secretion in intestinal-derived chylomicrons. Furthermore, phospholipid-rich whole eggs will enhance spinach-derived PQ bioavailability compared with vegetable oil, and will be most functionally responsible for the benefits of eggs to enhance nutrient absorption. Additionally, egg whites will more greatly promote nutrient bioaccessibility compared with spinach alone.

To test this, our specific aim is to assess egg-mediated improvements in PQ bioavailability by conducting a cross-over pharmacokinetic study in healthy men and women. In Study Arms 1-4, participants will ingest deuterium-labeled spinach (containing 500 μg PQ) with 0, 1, 2, or 3 hardboiled eggs (containing 0, 4.8, 9.6, or 14.4 g total fat, respectively). In Study Arm 5, participants will ingest spinach alone followed by 1 egg 3-hours later. In Study Arm 6, participants will ingest spinach with 1 egg followed by another egg 3-hours later. In Study Arm 7, participants will ingest spinach with two egg whites. In Study Arm 8, participants will ingest spinach with 9.6 grams of vegetable oil. Thus, Study Arms 1-4 will test the dose-dependent effects of eggs on PQ bioavailability, Study Arms 5-6 (with comparison to Study Arms 1 and 2) will test the 'timing'-dependent effects of eggs on PQ bioavailability, and Study Arms 7-8 will test the matrix effect on PQ bioavailability. Eucaloric diets will be controlled for PQ intakes for 3 d prior to and during the initial 24 h of each trial to minimize heterogeneity of pharmacokinetic responses. Spinach-derived deuterium-labeled PQ will be measured in plasma and isolated chylomicrons collected at timed intervals from 0-72 h post-meal ingestion, and biomarkers of antioxidant status and oxidative distress will be assessed at baseline (0 h) of each trial. Outcomes from this study are expected to establish that egg lipids substantially enhance plant-derived PQ bioavailability (based on AUC0-72 h, Cmax, and % estimated absorption) independent of any changes in oxidative distress.

The rationale for this study is that, by establishing the efficacy of eggs and egg yolk lipids to potentiate plant-derived fat-soluble nutrient bioavailability, a strong framework will exist for an easily implementable health-promoting food pairing strategy to overcome malnutrition of PQ.

Conditions

Nutritional Requirements

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Zero hard-boiled egg

Deuterium-labeled spinach containing 500 μg PQ will be ingested alone prior to the 72-h pharmacokinetics trial.

Group Type: EXPERIMENTAL

Zero hard-boiled egg at 0 h

Intervention Type: OTHER

No eggs will be consumed on test day along with spinach consumption

One hard-boiled egg at 0 h

Deuterium-labeled spinach containing 500 μg PQ will be ingested along with one hard-boiled egg prior to the 72-h pharmacokinetics trial.

Group Type: EXPERIMENTAL

One hard-boiled egg at 0 h

Intervention Type: OTHER

One egg will be consumed on test day along with spinach consumption

Two hard-boiled eggs at 0 h

Deuterium-labeled spinach containing 500 μg PQ will be ingested with two whole eggs (9.6 g fat) prior to the 72-h pharmacokinetics trial.

Group Type: EXPERIMENTAL

Two hard-boiled eggs at 0 h

Intervention Type: OTHER

Two eggs will be consumed on test day along with spinach consumption

Three hard-boiled eggs at 0 h

Deuterium-labeled spinach containing 500 μg PQ will be ingested along with three hard-boiled eggs prior to the 72-h pharmacokinetics trial.

Group Type: EXPERIMENTAL

Three hard-boiled eggs at 0 h

Intervention Type: OTHER

Three eggs will be consumed on test day along with spinach consumption

One hard-boiled egg at 3 h

Deuterium-labeled spinach containing 500 μg PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by one hard-boiled egg 3 hours after spinach consumption.

Group Type: EXPERIMENTAL

One hard-boiled egg at 3 h

Intervention Type: OTHER

One egg will be consumed on test day three hours after spinach consumption

One hard-boiled egg at 0 h + One hard-boiled egg at 3 h

Deuterium-labeled spinach containing 500 μg PQ will be ingested along with one hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by one egg 3 hours after spinach consumption.

Group Type: EXPERIMENTAL

One hard-boiled egg at 0 h + One hard-boiled egg at 3 h

Intervention Type: OTHER

Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption

Two egg whites at 0 h

Deuterium-labeled spinach containing 500 μg PQ will be ingested along with two egg whites prior to the 72-h pharmacokinetics trial.

Group Type: EXPERIMENTAL

Two egg whites at 0 h

Intervention Type: OTHER

Two egg whites will be consumed on test day along with spinach consumption

Vegetable oil at 0 h

Deuterium-labeled spinach containing 500 μg PQ will be ingested along with 9.6 grams of vegetable oil prior to the 72-h pharmacokinetics trial.

Group Type: EXPERIMENTAL

Vegetable oil at 0 h

Intervention Type: OTHER

9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption

Interventions

Zero hard-boiled egg at 0 h

No eggs will be consumed on test day along with spinach consumption

Intervention Type: OTHER

One hard-boiled egg at 0 h

One egg will be consumed on test day along with spinach consumption

Intervention Type: OTHER

Two hard-boiled eggs at 0 h

Two eggs will be consumed on test day along with spinach consumption

Intervention Type: OTHER

Three hard-boiled eggs at 0 h

Three eggs will be consumed on test day along with spinach consumption

Intervention Type: OTHER

One hard-boiled egg at 3 h

One egg will be consumed on test day three hours after spinach consumption

Intervention Type: OTHER

One hard-boiled egg at 0 h + One hard-boiled egg at 3 h

Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption

Intervention Type: OTHER

Two egg whites at 0 h

Two egg whites will be consumed on test day along with spinach consumption

Intervention Type: OTHER

Vegetable oil at 0 h

9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Body Mass Index (BMI) = 19-25 kg/m2
• Normolipidemic (total cholesterol <240 mg/dL; triglyceride <150 mg/dL)
• Fasting glucose <100 mg/dL
• Normal hematocrit level (41%-50% for men and 36%-48% for women)
• Normal hemoglobin level (13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women)
• No use of dietary supplements for >1 month
• No use of medications that affect lipid or glucose metabolism
• Non-smoker
• No history of gastrointestinal disorders

Exclusion Criteria

• Egg allergy
• Alcohol intake > 2 drinks per day
• Aerobic activity >7 h/wk
• Body mass change >2 kg in the past 1 month
• Women who are pregnant, lactating, or initiated or changed birth control in the past 3 month
• Vegetarian

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ohio State University

OTHER

Sponsor Role: lead

Responsible Party

Richard Bruno

Professor and Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Richard Bruno, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Locations

Bruno Lab

Columbus, Ohio, United States

Countries

United States

Other Identifiers

2019H0504-B

Identifier Type: -

Identifier Source: org_study_id